Skip to main content
Erschienen in: Diabetologia 3/2012

Open Access 01.03.2012 | Meta-analysis

Reno-protective effects of renin–angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis

verfasst von: P. Vejakama, A. Thakkinstian, D. Lertrattananon, A. Ingsathit, C. Ngarmukos, J. Attia

Erschienen in: Diabetologia | Ausgabe 3/2012

Abstract

Aims/hypothesis

This meta-analysis aimed to compare the renal outcomes between ACE inhibitor (ACEI)/angiotensin II receptor blocker (ARB) and other antihypertensive drugs or placebo in type 2 diabetes.

Methods

Publications were identified from Medline and Embase up to July 2011. Only randomised controlled trials comparing ACEI/ARB monotherapy with other active drugs or placebo were eligible. The outcome of end-stage renal disease, doubling of serum creatinine, microvascular complications, microalbuminuria, macroalbuminuria and albuminuria regression were extracted. Risk ratios were pooled using a random-effects model if heterogeneity was present; a fixed-effects model was used in the absence of heterogeneity.

Results

Of 673 studies identified, 28 were eligible (n = 13–4,912). In direct meta-analysis, ACEI/ARB had significantly lower risk of serum creatinine doubling (pooled RR = 0.66 [95% CI 0.52, 0.83]), macroalbuminuria (pooled RR = 0.70 [95% CI 0.50, 1.00]) and albuminuria regression (pooled RR 1.16 [95% CI 1.00, 1.39]) than other antihypertensive drugs, mainly calcium channel blockers (CCBs). Although the risks of end-stage renal disease and microalbuminuria were lower in the ACEI/ARB group (pooled RR 0.82 [95% CI 0.64, 1.05] and 0.84 [95% CI 0.61, 1.15], respectively), the differences were not statistically significant. The ACEI/ARB benefit over placebo was significant for all outcomes except microalbuminuria. A network meta-analysis detected significant treatment effects across all outcomes for both active drugs and placebo comparisons.

Conclusions/interpretation

Our review suggests a consistent reno-protective effect of ACEI/ARB over other antihypertensive drugs, mainly CCBs, and placebo in type 2 diabetes. The lack of any differences in BP decrease between ACEI/ARB and active comparators suggest this benefit is not due simply to the antihypertensive effect.
Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1007/​s00125-011-2398-8) contains peer-reviewed but unedited supplementary material, which is available to authorised users.
Abkürzungen
ACEI
ACE inhibitor
ARB
Angiotensin II receptor blocker
BB
Beta-blocker
CCB
Calcium-channel blocker
DBP
Diastolic BP
d-CCB
Dihydropyridine CCB
ESRD
End-stage renal disease
nd-CCB
Non-dihydropyridine CCB
RAS
Renin–angiotensin system
RCT
Randomised controlled trial
SBP
Systolic BP
UKPDS
UK Prospective Diabetes Study

Introduction

Diabetic nephropathy is a significant health and economic burden across the world. The prevalence of micro- and macroalbuminuria in type 2 diabetes is as high as 37–40% in western countries and 57.4–59.8% in Asian countries [13]. Microalbuminuria is a well-established risk factor for cardiovascular disease and is also associated with end-stage renal disease (ESRD) [47]. Preventive treatments have been prescribed for type 2 diabetes with or without hypertension with the aim of lowering BP, and delaying or even preventing the progression of diabetic nephropathy.
The reno-protective effects of renin–angiotensin system (RAS) blockers in type 2 diabetes have been controversial [8]. A few systematic reviews have been conducted [911], but these reviews pooled studies with mixed populations of participants with type 1 and type 2 diabetes, with and without diabetic nephropathy, and the focus was mainly on surrogate rather than clinical outcomes. We therefore conducted a systematic review and meta-analysis comparing the effects of ACE inhibitor (ACEI)/angiotensin II receptor blocker (ARB) with other antihypertensive drugs and placebo on ESRD, doubling of serum creatinine, microvascular complications, micro- and macroalbuminuria and regression of albuminuria.

Methods

Study selection

English-language publications were identified from Medline (1949–July 2011) and Embase (1974–April 2011) using PubMed and Ovid search engines. Search terms and strategies for Medline were as follows: (type 2 diabetes or type 2 diabetes mellitus or type 2 DM or non insulin dependent diabetes) and (ACEI or angiotensin-converting enzyme inhibitors or ACE inhibitors or ARB or angiotensin receptor blockers*) and (nephropathy or overt nephropathy or microalbuminuria or macroalbuminuria or microvascular complications or doubling serum creatinine or ESRD or end-stage renal disease or urinary albumin excretion). We also searched for any additional studies in the reference lists of identified publications. Data from the most recent or the most complete report by the same authors were used. We restricted our searches to clinical trials. Studies with the following criteria were included: type 2 diabetic adult individuals, randomised trial comparing any single ACEI/ARB with other single agents (e.g. beta-blocker [BB], calcium-channel blocker [CCB], diuretics) or placebo, had at least one of the following outcomes (microalbuminuria, macroalbuminuria, albuminuria regression, microvascular complications, serum creatinine doubling and/or ESRD), and reported number of patients and events in each treatment arm. Studies were excluded if they were crossover trials, used dual therapies or compared different dosages of ACEI/ARB.
Outcome measures
The outcomes of interest were ESRD, doubling of serum creatinine, microvascular complications, macroalbuminuria, microalbuminuria and regression of albuminuria. ESRD was defined as a requirement for renal replacement therapy or dialysis. Doubling of serum creatinine was defined as an increase in serum creatinine level of at least two times compared with baseline level. Microvascular complications were defined as a composite of having nephropathy and/or retinopathy. Microalbuminuria was defined as urine albumin excretion rate of 30–300 mg/24 h for 24 h urine collection, 3.5–35 mg/mmol for urinary albumin/creatinine ratio from a spot urine collection, or 20–199 μg/min for timed urine collection. Macroalbuminuria was defined as urine albumin excretion rate ≥300 mg/24 h, ≥25 mg/mmol creatinine or ≥200 μg/min for the same specimens, respectively. Regression of albuminuria was defined as a change from a higher to a lower stage of albuminuria.

Data extraction

Two investigators (P. Vejakama and D. Lertrattananon) independently extracted data, including study and participant characteristics (e.g. age, BP, albuminuria stage, serum glucose, and HbA1c) and numbers of events across intervention groups. Discrepancies were discussed with a third party (A. Thakkinstian) and resolved by consensus.

Risk of bias assessment

Risk of bias was assessed using the Cochrane Collaboration’s tool addressing six domains: sequence generation, allocation concealment, blinding of participants/outcome assessors, incomplete outcome, selective outcome reporting and other source of bias. Two investigators (P. Vejakama and D. Lertrattananon) independently completed the assessments; discrepancies were discussed with a third party (A. Thakkinstian) and resolved by consensus.

Statistical analysis

For direct meta-analysis, the intervention of interest was ACEI/ARB monotherapy, while the comparator group was any antihypertensive drug or placebo. Pooled RRs were used to compare treatment effects. The Q test and I 2 statistic were used to assess the presence and degree of heterogeneity. If heterogeneity was present or I 2 >25%, the random-effects model was applied, otherwise the fixed-effects model was used. Sources of heterogeneity were explored using meta-regression. The Harbord test and a funnel plot were applied to assess publication bias [12]. If either suggested asymmetry of the funnel, contour-enhanced funnel plots were used to distinguish the cause of asymmetry (i.e. heterogeneity and reporting bias) [13, 14].
A network meta-analysis [1517] was performed to compare indirectly all treatment effects. Summary data for treatments and outcomes were expanded to the individual patient level. A binary regression analysis was applied and the pooled RRs and 95% CIs were estimated. All analyses were performed using STATA version 11 (Stata Corp., College Station, TX, USA). p values less than 0.05 were considered statistically significant, except for the test of heterogeneity where p < 0.10 was used.

Results

Of the 673 articles located, full papers of 153 plus four additional studies from reference lists were reviewed, leading to data pooling for 28 studies (see Fig. 1). The characteristics of these studies are described in Table 1. The major ACEI/ARBs used were enalapril (32%), followed by lisinopril (10.7%) and ramipril (10.7%). The majority of comparators were dihydropyridine CCBs (d-CCBs; 43%), placebo (39%), or BB/diuretic/non-dihydropyridine CCBs (nd-CCBs; 18%). Numbers of individuals are summarised according to the treatments and outcomes of interest (electronic supplementary material [ESM] Tables 16).
Table 1
Characteristics of studies in the meta-analysis
Author(s), year [reference]
Type of participant at baseline
Intervention (mg/day)
Comparator (mg/day)
Outcomes
Follow-up (years)
Age (years)
HbA1c, % (mmol/mmol)
Renal function
Albuminuria
HT
UKPDS, 1998 [26]
56
7.0 (53)
Normoalb Microalb Macroalb
Yes
Captopril (25–50)
Atenolol (50–100)
Microalb, Macroalb, ESRD
8.4
HOPE, 2000 [24]
65
93.9a
Normoalb Microalb
Mix
Ramipril (10)
Placebo
Macroalb, ESRD
4.5
Ahmad et al, 1997 [41]
50
8.1 (65)
124b
Microalb
No
Enalapril (10)
Placebo
Macroalb
5
Baba et al, 2001 [25]
60
Normoalb Microalb
Yes
Enalapril (5–50)
Nifedipine R (20–60)
Microalb, Macroalb, albuminuria regression
2
Bakris et al, 1996 [20]
63
10.7 (93)
63.6c
Macroalb
Yes
Lisinopril
Verapamil/diltiazem Atenolol
ESRD
6
Chan et al, 2000 [21]
58
Normoalb Microalb Macroalb
Yes
Enalapril (10–40)
Nifedipine SR (40–80)
Microalb, Macroalb, albuminuria regression, ESRD
5
Fogari et al, 2005 [27]
60
6.9 (52)
Microalb
Yes
Lisinopril (10)
Manidipine (10)
Albuminuria regression
2
Fogari et al, 2002 [28]
63
7.1 (54)
88.4a
Microalb
Yes
Fosinopril (10–30)
Amlodipine (5–15)
Albuminuria regression
4
Fogari et al, 1999 [40]
56
7.2 (55)
43.8c
Macroalb
Yes
Ramipril (5)
Nitrendipine 20
ESRD
2
Lacourciere et al, 1993 [22],
57
9.3 (78)
77.8a
Macroalb
Yes
Captopril (50–100)
Metoprolol (50–100) HCTZ (25–50)
Microalb, Macroalb
3
Lebovitz et al, 1994 [42]
   
Normoalb Microalb
Yes
Enalapril (5–40)
Placebo
Macroalb
3
Marre et al, 2004 [29]
60
7.8 (62)
92.5c
Microalb Macroalb
Mixed
Ramipril (1.25)
Placebo
Albuminuria regression, ESRD
4
Marre et al, 2004 [38]
65
7.6 (60)
89.2a
Microalb
Yes
Enalapril (10)
Indapamide (1.5)
Macroalb, albuminuria regression
1
Mosconi et al, 1996 [44]
64.6b
Microalb
Yes
Enalapril (5–20)
Nitrendipine (10–40)
Albuminuria regression
2
Nielson et al, 1997 [30]
61
8.6 (71)
74.5b
Macroalb
Yes
Lisinopril (10–20)
Atenolol (50–100)
ESRD
3.5
Ogawa et al, 2007 [45]
61
6.8 (51)
65.8
Microalb
Yes
Temocapril (4)
Nifedipine CR (40)
Albuminuria regression
2
Ravid et al, 1998 [31]
55
9.3 (78)
107.7c
Normoalb
No
Enalapril (10)
Placebo
Microalb
6
Ravid et al, 1993 [32]
44
10.4 (90)
104.6a
Microalb
No
Enalapril (10)
Placebo
Macroalb
5
Ruggenenti et al, 2004 [43]
62
5.8 (40)
79.6a
Normoalb
Yes
Trandolapril (2)
Verapamil SR (240), placebo
Microalb
3.6
Shiba et al, 2000 [23]
61
8.1 (65)
Normoalb Microalb
Yes
Delapril (60)
Manidipine (10)
Macroalb
2
Brenner et al, 2001 [34]
60
8.4 (68)
168a
Macroalb
 
Losartan (50–100)
Placebo
ESRD, doubling Scr
3.4
Jerums et al, 2004 [36]
53
8.1 (65)
92
Microalb
No
Perindopril
Nifedipine
Macroalb, albuminuria regression
6
Haller et al, 2011 [39]
57.7
7.7 (61)
84.9
Normoalb
Mixed
Olmesartan (40)
Placebo
Microalb, doubling Scr
3.2
Lewis et al, 2001 [33]
59
8.2 (66)
147.6a
Proteinuria
Yes
Irbesartan
Amlodipine, placebo
Doubling Scr, ESRD
2.6
Kashiwagi, 2007 [18]
62
Microalb
Yes
Valsartan
Amlodipine
Albuminuria regression
0.5
Bilous et al, 2009 [35]
56.9
90
Normoalb
Mixed
Candesartan
Placebo
Microalb
4.7
Sjolie et al, 2008 [37]
57
8.2 (66)
Normoalb
Mixed
Candesartan
Placebo
Microvascular complication
4.7
Estacio et al, 2000 [19]
58
11.6 (103)
Normoalb Microalb Macroalb
Yes
Enalapril (5–40)
Nisoldipine (10–60)
Microalb, Macroalb
5.3
aSerum creatinine (mmol/l)
bEstimated GFR (ml min−1 1.73 m−2)
cCreatinine clearance (ml/min)
HCTZ, hydrochlorothiazide; HT, hypertension; Macroalb, Macroalbuminuria; Microalb, microalbuminuria; Normoalb, normoalbuminuria; Scr, serum creatinine
The assessments of risk of bias are described in ESM Table 7. Problems with incomplete outcome reports were least frequent in 2/28 (7.1%) studies [18, 19], followed by other sources of bias in 5/28 (17.9%) [18, 2023] and selective reporting of outcomes in 5/28 (17.9%) [18, 21, 22, 24, 25]. Although all studies were randomised controlled trials (RCTs), only 14 (50.0%) studies clearly described randomisation [21, 2537] and allocation concealment [21, 22, 2629, 31, 3339].

Direct meta-analysis

ESRD Nine studies [20, 21, 24, 26, 29, 30, 33, 34, 40] reported the effect of ACEI/ARB on ESRD (n = 13,295). Of these, five studies [20, 21, 26, 30, 40] compared ACEI with other antihypertensive drugs (three BB, two d-CCB), three [24, 29, 34] compared ACEI with placebo, and one [33] compared ARB with d-CCB and placebo (ESM Table 1).
Six studies [20, 21, 26, 30, 33, 40] directly compared ACEI/ARB with other active drugs (n = 1,090 vs 1,055); four were trials that studied patients with macroalbuminuria whereas the other two studied mixed patients with micro- and macroalbuminuria.
The treatment effects were homogeneous (χ 2 = 1.54, df = 5, p = 0.908, I 2 = 0.0%), suggesting that ACEI/ARB reduced the risk of ESRD by 18% (pooled RR = 0.82 [95% CI 0.64, 1.05]; see Fig. 2a). However, this result was not statistically significant (Table 2). Neither the Harbord test nor a funnel plot (ESM Fig. 1a) suggested publication bias (coefficient −0.001, SE = 0.436, p = 0.998).
Table 2
Summarised characteristics of studies and direct pooling treatment effects according to clinical outcomes
Dichotomous outcomes
Number of studies
Sample size
RR (95% CI)
ESRD
 ACEI/ARB vs other active drugs
6
2,147
0.82 (0.64, 1.05)
 ACEI/ARB vs placebo
4
10,581
0.80 (0.69, 0.93)
Doubling of serum creatinine
 ACEI/ARB vs other active drugs
2
1,198
0.66 (0.53, 0.83)
 ACEI/ARB vs placebo
4
10,594
0.76 (0.69, 0.84)
Major microvascular complications
 ACEI/ARB vs other active drugs
1
758
1.28 (0.81, 2.03)
 ACEI/ARB vs placebo
4
6,489
0.85 (0.74, 0.97)
Macroalbuminuria
 ACEI/ARB vs other active drugs
8
1,211
0.71 (0.50, 1.00)
 ACEI/ARB vs placebo
5
3,868
0.67 (0.54, 0.83)
Microalbuminuria
 ACEI/ARB vs other active drugs
6
1,430
0.84 (0.61, 1.15)
 ACEI/ARB vs placebo
4
6,762
0.82 (0.64, 1.05)
Albuminuria regression
 ACEI/ARB vs other active drugs
9
1,286
1.16 (0.99, 1.39)
 ACEI/ARB vs placebo
2
1,238
1.17 (1.00, 1.37)
For placebo controls, pooled estimates based on four studies [24, 29, 33, 34] (n = 5,581 vs 5,569) demonstrated homogeneous treatment effects (χ 2 = 1.11, df = 3, p = 0.774, I 2 = 0.0%; Fig. 2b) despite a mix of patients with normo-, micro- and macroalbuminuria. ACEI/ARB significantly decreased the risk of ESRD by 20% (pooled RR = 0.80 [95% CI 0.69, 0.93]; Table 2). Although the Harbord test was not significant (coefficient 1.220, SE = 0.311, p = 0.059), the contour-enhanced funnel plot showed asymmetry (ESM Fig. 1b). One high-precision study fell in the significant area (grey shading) whereas the other three (one high and two low precision) were in the non-significant area. Applying ‘trim and fill’ suggested two low-precision studies (square symbols) were missing; adding these studies yielded a pooled RR of 0.78 (95% CI 0.68, 0.91) with I 2 = 0%.
Doubling of serum creatinine
Six studies [20, 24, 29, 33, 34, 39] reported the effect of ACEI/ARB vs other antihypertensive drugs on doubling of serum creatinine (n = 16,216), and five studies [24, 29, 33, 34, 39] reported ACEI/ARB vs placebo (ESM Table 2).
The treatment effects of ACEI/ARB vs antihypertensive drugs (n = 597 vs 601) were homogeneous (χ 2 = 0.76, df = 1, p = 0.382, I 2 = 0.0%) with a pooled RR of 0.66 (95% CI 0.53, 0.83; Fig. 2b), suggesting a significant reduction in risk of 34%.
The ACEI/ARB effects were also present when compared with placebo (n = 7,831 vs 7,784). The pooled RR was 0.76 (95% CI 0.69, 0.84), indicating a 24% lower risk of serum creatinine doubling. The pooled effect was homogeneous (χ 2 = 1.67, df = 4, p = 0.796, I 2 = 0.0%) without publication bias (Harbord test coefficient = 0.629, SE = 0.908, p = 0.538; ESM Fig. 2).
Microvascular complications
Of five studies [24, 26, 31, 32, 37] (n = 6,489), only one [26] compared ACEI/ARB with active drug; the other four [24, 31, 32, 37] compared ACEI/ARB with placebo (ESM Table 3).
Compared with placebo controls (n = 2,847 vs 2,884), ACEI/ARB significantly reduced the risk of microvascular complications by 15% (pooled RR = 0.85 [95% CI 0.76, 0.97]), with low heterogeneity (χ 2 = 3.34, df = 3, p = 0.342, I 2 = 10.3%; Fig. 2c) and without publication bias (Harbord test coefficient = −1.51, SE = 0.53, p = 0.105; ESM Fig. 3). In addition, the ACEI/ARB group (n = 2,884) had a significantly lower risk of retinopathy (13% lower, pooled RR = 0.87 [95% CI 0.76, 0.99]) with low heterogeneity (χ 2 = 3.51, df = 3, p = 0.319, I 2 = 14.6%).
Macroalbuminuria
Twelve studies [19, 2126, 32, 36, 38, 41, 42] reported ACEI/ARB effects on macroalbuminuria (n = 5,151) with ACEI/ARB vs other therapies (five with d-CCB, one with diuretic, one with BB and one with BB/diuretic) in eight studies [19, 2123, 25, 26, 36, 38] and placebo in five studies [24, 32, 36, 41, 42] (ESM Table 4). Eight trials [19, 22, 25, 26, 32, 36, 38, 41] (n = 1,401) studied patients with microalbuminuria, and four [21, 23, 24, 42] (n = 3,761) studied mixed patients with normo- and microalbuminuria.
Direct pooled estimates of treatment effects between ACEI/ARB and other antihypertensive drugs (n = 641 vs 653) of eight trials [19, 2123, 25, 26, 36, 38] were homogeneous (χ 2 = 5.24, df = 7, p = 0.631, I 2 = 0.0%; Fig. 2d) with borderline significant risk reduction of 29% (pooled RR = 0.71 [95% CI 0.50, 1.00]). Neither the Harbord test nor the funnel plot suggested publication bias (coefficient = −0.733, SE = 0.828, p = 0.410; ESM Fig. 4a).
Among five placebo-controlled trials [24, 32, 36, 41, 42] (n = 1,950 vs 1,918), the pooled RR was 0.45 (95% CI 0.26, 0.79) with moderate heterogeneity (χ 2 = 8.64, df = 4, p = 0.071, I 2 = 53.7%; Fig. 2d). This suggested that ACEI/ARB significantly reduced risk of macroalbuminuria by 55%. The Harbord test suggested asymmetry of the funnel plot (coefficient = −2.043, SE = 0.547, p = 0.033). The contour-enhanced funnel plot showed that one-half of the studies included were in the high- and non-significance areas (ESM Fig. 4b), suggesting treatment-effect heterogeneity. Meta-regression analysis fitting type of patient (microalbuminuria and mixed patients) reduced the degree of heterogeneity (I 2) from 53.7% to 0%. Subgroup analysis performed in patients with microalbuminuria and mixed micro- and macroalbuminuria yielded pooled RRs of 0.31 (95% CI 0.18, 0.57) and 0.45 (95% CI 0.26, 0.79), respectively.
Microalbuminuria
Nine studies [19, 21, 22, 25, 26, 31, 35, 39, 43] had microalbuminuria outcomes (n = 7,891): six [19, 21, 22, 25, 26, 43] looking at ACEI vs other antihypertensive drugs, two looking at ACEI vs placebo [31, 43] and two looking at ARB vs placebo [35, 39] (ESM Table 5).
The pooled treatment effects between ACEI/ARB and other antihypertensive drugs were somewhat heterogeneous (χ 2 = 7.70, df = 5, p = 0.174, I 2 = 35.1%) with a pooled RR of 0.84 (95% CI 0.61, 1.15) (Table 2 and Fig. 2e). The Harbord test suggested no asymmetry of the funnel plot (coefficient = −0.281, SE = 1.367, p = 0.847; ESM Fig. 5a).
Compared with placebo in four studies [31, 35, 39, 43] (n = 3,290 vs 3,472), the pooled effect of ACEI/ARBs [24, 28, 32, 37] was 0.82 (95% CI 0.64, 1.05; Fig. 2e) with moderate heterogeneity (χ 2 = 5.93, df = 3, p = 0.115, I 2 = 49.4%). Meta-regression could not identify the source of the heterogeneity. The Harbord test suggested asymmetry of the funnel (coefficient = −2.626, SE = 0.360, p = 0.018), and the contour-enhanced funnel plot suggested that this heterogeneity might be the cause of the asymmetry (ESM Fig. 5b).
Albuminuria regression
Ten studies [18, 21, 25, 2729, 36, 38, 44, 45] reported regression of albuminuria (n = 3,710; ESM Table 6).
The treatment effect between ACEI/ARB and other antihypertensive drugs, based on nine studies [18, 21, 25, 27, 28, 36, 38, 44, 45] (n = 646 vs 640), was homogeneous (χ 2 = 8.74, df = 8, p = 0.365, I 2 = 8.4%) with a borderline non-significant effect of 16% (pooled RR = 1.16 [95% CI 0.99, 1.39]; see Table 2 and Fig. 2f). Neither the Harbord test nor a funnel plot suggested publication bias (coefficient = −0.086, SE = 0.718, p = 0.907; ESM Fig. 6).
For the placebo-controlled trials (n = 947 vs 948), the likelihood of albuminuria regression was 17% higher with ACEI/ARB, which was on the borderline of non-significance (RR = 1.17 [95% CI 1.00, 1.37]; Table 2).

Network meta-analysis

ESRD
A network meta-analysis was applied to assess all treatment comparisons, (ESM Fig. 7a and ESM Table 8). Arrows and tails refer to interventions and comparators, bold and dashed lines refer to direct and indirect comparisons, respectively. Numbers under the line refer to the number of studies for the direct comparator data, whereas numbers above the line indicate pooled RRs. The analysis suggested that the ACEI/ARB (n = 6,092) significantly decreased the risk of ESRD when compared with d-CCB (n = 644) and placebo (n = 5,569,) with pooled RRs of 0.25 (95% CI 0.07, 0.96) and 0.77 (95% CI 0.64, 0.92), respectively. However, the risk of ESRD was 2.00 (95% CI 0.35, 11.55) times higher, but not significantly so, compared with the BB group (n = 411). Comparing ACEI/ARB with all antihypertensive drugs (dCCB + BB) resulted in 62% significantly lower risk of ESRD (pooled RR = 0.38 [95% CI 0.31, 0.47]).
Pooling mean BPs from four studies [21, 26, 30, 40] showed non-significant differences between groups, with mean differences of 1.27 (95% CI −1.42, 3.95) for systolic BP (SBP) and −0.71 (95% CI −3.88, 2.46) for diastolic BP (DBP).
Doubling of serum creatinine
ESM Fig. 7b and ESM Table 8 show that ACEI/ARBs (n = 7,831) significantly reduced the risk of serum creatinine doubling by 77% (pooled RR = 0.23 [95% CI 0.09, 0.57]), 72% (pooled RR = 0.28 [95% CI 0.11, 0.71]), and 21% (pooled RR = 0.79 [95% CI 0.75, 0.84]) compared with d-CCB (n = 567), nd-CCB/BB (n = 34), and placebo (n = 7,784), respectively. Combining all antihypertensive drugs (n = 601) and comparing with ACEI/ARB resulted in 77% significantly lower risk (pooled RR = 0.23 [95% CI 0.09, 0.58]).
Microvascular complications
The number of participants in each treatment arm is described in ESM Table 3, with total number of patients in ACEI/ARB and placebo of 3,284 vs 2,847, respectively. ACEI/ARBs significantly reduced the risk of microvascular complications by 19% (pooled RR = 0.81 [95% CI 0.71, 0.92]) when compared with placebo, but increased the risk almost twofold when compared with BB (ESM Fig. 7c and ESM Table 8).
Macroalbuminuria
Network meta-analysis was performed based on 12 studies [19, 2126, 32, 36, 38, 41, 42] (n = 5,151; ESM Table 4). ACEI/ARBs (n = 2,580) significantly reduced macroalbuminuria by 29% (pooled RR = 0.71 [95% CI 0.62, 0.83]) compared with BB/diuretic (n = 441), 55% (pooled RR = 0.45 [95% CI 0.29, 0.70]) vs d-CCB (n = 212), and 33% (pooled RR = 0.67 [95% CI 0.49, 0.92]) vs placebo (n = 1,918; ESM Fig. 7d and ESM Table 8). The ACEI/ARBs significantly reduced macroalbuminuria by 40% (pooled RR = 0.60 [95% CI 0.47, 0.77]) compared with all antihypertensive drugs (n = 653).
Pooling SBP and DBP in three studies [21, 38, 41], the mean SBP and DBP differences were 2.82 (95% CI 0.32, 5.31) and 0.33 (95% CI −0.93, 1.60) mmHg, respectively.
Microalbuminuria
Based on pooling of results from nine studies [19, 21, 22, 25, 26, 31, 35, 39, 43] (n = 7,891), ACEI/ARB (n = 3,704) had significantly better benefit than d-CCB (n = 238) with a pooled RR of 0.50 (95% CI 0.38, 0.65), but significantly worse outcomes than BB (i.e. favouring BB ) with the pooled RR of 0.48 (95% CI 0.35, 0.66; ESM Fig. 7e and ESM Table 8). When compared with nd-CCB (n = 303) and placebo (n = 3,472), ACEI/ARBs did not reduce microalbuminuria with pooled RRs of 0.93 (95% CI 0.71, 1.22) and 1.01 (95% CI 0.82, 1.25), respectively. Compared with all antihypertensive drugs, the ACEI/ARB significantly reduced the risk by 39% (pooled RR = 0.61 [95% CI 0.45, 0.83]).
Regression of albuminuria
Using data from ten studies (n = 3,710) [18, 21, 25, 2729, 36, 38, 44, 45], ACEI/ARB (n = 1,582) significantly promoted regression of albuminuria compared with placebo (n = 948), but not with diuretic (n = 283); RRs were 1.35 (95% CI 1.07, 1.70) in favour of ACEI/ARB and 1.28 (95% CI 1.02, 1.60) in favour of diuretic, respectively (ESM Fig. 7f and ESM Table 8). The pooled RR was1.16 (95% CI 0.83, 1.63) for ACEI/ARB vs d-CCB (n = 357).
In six of ten studies where data were available [21, 2729, 44, 45], the mean SBP was significantly higher for ACEI/ARB (mean difference = 2.35 [95% CI 1.07, 3.64]) than placebo but not so for DBP (mean difference = 0.54 mmHg [95% CI −0.40, 1.48 mmHg]).

Discussion

The direct and indirect comparisons in our study confirm the clear benefit of ACEI/ARB over placebo for all outcomes (ESRD, serum creatinine doubling, microvascular complications, macroalbuminuria and regression of albuminuria) except microalbuminuria. The lack of a statistically significant treatment effect for microalbuminuria outcome is likely to result partly from the heterogeneity of treatment effects across the studies.
Our study extends the results of Strippoli et al. [11], who showed borderline significant benefit for ACEI/ARB vs placebo for doubling of serum creatinine (RR = 0.79 [95% CI 0.75, 0.84] vs 0.60 [95% CI 0.34, 1.05]) and ESRD (RR = 0.77 [95% CI 0.64, 0.92] vs 0.64 [95% CI 0.4, 1.03]). The addition of new data and the use of network meta-analysis methods increase the power and allow us to demonstrate the reno-protective effects of RAS blockade more confidently.
The major contribution of our study is in teasing out the potential reno-protective effect of ACEI/ARBs over other antihypertensive drugs. Overall, the direct meta-analysis suggests a potential benefit of ACEI/ARB in reducing macroalbuminuria and doubling of serum creatinine, and in promoting regression of albuminuria. The results of network meta-analysis suggest additional benefits of the ACEI/ARB in reducing the risk of ESRD. These benefits contradict the previous meta-analysis [9], which found reno-protective effects of ACEI/ARB in patients without diabetes but not in patients who had already developed diabetic nephropathy. This discrepancy with previous work may be due partly to the addition of new data, thereby improving power, or may be driven partly by the fact that the major active comparators were CCBs; in some comparisons, BBs and diuretics are significantly better than ACEI/ARBs, though the numbers in these comparisons are small and driven largely by the UK Prospective Diabetes Study (UKPDS).
In the studies that reported BP change, there was no significant difference in BP decrease between ACEI/ARB and other antihypertensive drugs, suggesting that there is a specific reno-protective effect of ACEI/ARBs beyond their antihypertensive effect. This runs contrary to the conclusion of Casas et al. [9], who found the effect of RAS blockade to depend on its BP-lowering effect. In their study, Casas et al. showed that the benefit of RAS blockers compared with active control was associated with the extra degree of BP decrease. These results are hard to reconcile with summary-level data. It is of course possible for both conclusions to be true, i.e. the effect of RAS blockers is linked to the level of BP control but that for two agents that bring about the same drop in BP, RAS blockers would have an additional benefit. This possibility would be better teased out with a meta-analysis of individual patient data or a direct test of this hypothesis in a large-scale RCT.
Our study has some strengths. We have applied a network meta-analysis to increase the power of the tests and reduce type I errors [1517]. We applied a mixed model, which is thought to be the most appropriate method for this kind of pooling. The network method ‘borrows’ treatment information from other studies and increases the total sample size. As a result, treatment effects that could not be detected or treatment effects of borderline significance in direct meta-analysis could be identified. In addition, all possible treatment comparisons are mapped and displayed (see ESM Table 9). The weakness of our study is that despite the large overall numbers, some comparator groups still have small numbers, leading to poor precision of estimates. The lack of BP data for some studies also limits our ability to judge the specific reno-protective effects.
In conclusion, there appears to be a consistent benefit of ACEI/ARB on all outcomes in type 2 diabetes, including the ‘hard clinical endpoints’ of ESRD and doubling of serum creatinine, when compared with other antihypertensive drugs (mainly CCBs) and placebo, both in direct and indirect meta-analyses. This is seen in the context of no difference in BP decrease, suggesting a specific reno-protective effect. Other antihypertensives, particularly BBs and diuretics, may have even greater reno-protective effects but this needs to be investigated in further studies or individual patient meta-analysis.

Acknowledgements

This study was funded by a grant from the Multi-Sectoral Network for Non-Communicable Disease Control (NCD network) of Thailand.

Contribution statement

AT had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. PV, DL, AT and JA contributed to the study concept and design. AT and JA contributed to study supervision. PV, AT, DL and AI contributed to the acquisition of data. PV, AT, AI, CN and JA contributed to analysis and interpretation of data. PV, DL and AT contributed to the drafting of the manuscript. JA, AT, AI and CN contributed to the critical revision of the manuscript for important intellectual content. All authors gave final approval of the version to be published.

Duality of interest

The authors declare that there is no duality of interest associated with this manuscript. The funding organisation had no role in the design or conduct of the study.

Open Access

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
Open AccessThis is an open access article distributed under the terms of the Creative Commons Attribution Noncommercial License (https://​creativecommons.​org/​licenses/​by-nc/​2.​0), which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

© Springer Medizin

Bis 11. April 2024 bestellen und im ersten Jahr 50 % sparen!

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

© Springer Medizin

Bis 11. April 2024 bestellen und im ersten Jahr 50 % sparen!

e.Med Allgemeinmedizin

Kombi-Abonnement

Mit e.Med Allgemeinmedizin erhalten Sie Zugang zu allen CME-Fortbildungen und Premium-Inhalten der allgemeinmedizinischen Zeitschriften, inklusive einer gedruckten Allgemeinmedizin-Zeitschrift Ihrer Wahl.

© Springer Medizin

Bis 11. April 2024 bestellen und im ersten Jahr 50 % sparen!

Literatur
1.
Zurück zum Zitat Scheffel RS, Bortolanza D, Weber CS et al (2004) Prevalence of micro and macroangiopatic chronic complications and their risk factors in the care of outpatients with type 2 diabetes mellitus. Rev Assoc Med Bras 50:263–267PubMedCrossRef Scheffel RS, Bortolanza D, Weber CS et al (2004) Prevalence of micro and macroangiopatic chronic complications and their risk factors in the care of outpatients with type 2 diabetes mellitus. Rev Assoc Med Bras 50:263–267PubMedCrossRef
2.
Zurück zum Zitat Ubink-Veltmaat LJ, Bilo HJ, Meyboom-de Jong B (2004) Microalbuminuria in patients with type 2 diabetes mellitus in general practice. Ned Tijdschr Geneeskd 148:2026–2030PubMed Ubink-Veltmaat LJ, Bilo HJ, Meyboom-de Jong B (2004) Microalbuminuria in patients with type 2 diabetes mellitus in general practice. Ned Tijdschr Geneeskd 148:2026–2030PubMed
3.
Zurück zum Zitat Wu AY, Kong NC, de Leon FA et al (2005) An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) Study. Diabetologia 48:17–26PubMedCrossRef Wu AY, Kong NC, de Leon FA et al (2005) An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) Study. Diabetologia 48:17–26PubMedCrossRef
4.
Zurück zum Zitat Gall MA (1997) Albuminuria in non-insulin-dependent diabetes mellitus. Prevalence, causes, and consequences. Dan Med Bull 44:465–485PubMed Gall MA (1997) Albuminuria in non-insulin-dependent diabetes mellitus. Prevalence, causes, and consequences. Dan Med Bull 44:465–485PubMed
5.
Zurück zum Zitat Garg JP, Bakris GL (2002) Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med 7:35–43PubMedCrossRef Garg JP, Bakris GL (2002) Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med 7:35–43PubMedCrossRef
6.
Zurück zum Zitat Klausen K, Borch-Johnsen K, Feldt-Rasmussen B et al (2004) Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 110:32–35PubMedCrossRef Klausen K, Borch-Johnsen K, Feldt-Rasmussen B et al (2004) Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 110:32–35PubMedCrossRef
7.
Zurück zum Zitat Ravid M, Lang R, Rachmani R, Lishner M (1996) Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med 156:286–289PubMedCrossRef Ravid M, Lang R, Rachmani R, Lishner M (1996) Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med 156:286–289PubMedCrossRef
8.
Zurück zum Zitat Ruggenenti P, Perna A, Gherardi G, Benini R, Remuzzi G (2000) Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis 35:1155–1165PubMedCrossRef Ruggenenti P, Perna A, Gherardi G, Benini R, Remuzzi G (2000) Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis 35:1155–1165PubMedCrossRef
9.
Zurück zum Zitat Casas JP, Chua W, Loukogeorgakis S et al (2005) Effect of inhibitors of the renin–angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 366:2026–2033PubMedCrossRef Casas JP, Chua W, Loukogeorgakis S et al (2005) Effect of inhibitors of the renin–angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 366:2026–2033PubMedCrossRef
10.
Zurück zum Zitat Kunz R, Friedrich C, Wolbers M, Mann JF (2008) Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 148:30–48PubMed Kunz R, Friedrich C, Wolbers M, Mann JF (2008) Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 148:30–48PubMed
11.
Zurück zum Zitat Strippoli GF, Craig M, Deeks JJ, Schena FP, Craig JC (2004) Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 329:828PubMedCrossRef Strippoli GF, Craig M, Deeks JJ, Schena FP, Craig JC (2004) Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 329:828PubMedCrossRef
12.
Zurück zum Zitat Sterne JA, Sutton AJ, Ioannidis JP et al (2011) Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 343:d4002PubMedCrossRef Sterne JA, Sutton AJ, Ioannidis JP et al (2011) Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 343:d4002PubMedCrossRef
13.
Zurück zum Zitat Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L (2008) Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol 61:991–996PubMedCrossRef Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L (2008) Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol 61:991–996PubMedCrossRef
14.
Zurück zum Zitat Palmer TM, Peter JL, Sutton AJ, Moreno SG (2008) Contour-enhanced funnel plots in meta-analysis. Stata J 8:242–254 Palmer TM, Peter JL, Sutton AJ, Moreno SG (2008) Contour-enhanced funnel plots in meta-analysis. Stata J 8:242–254
15.
Zurück zum Zitat Lu G, Ades AE (2004) Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 23:3105–3124PubMedCrossRef Lu G, Ades AE (2004) Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 23:3105–3124PubMedCrossRef
16.
Zurück zum Zitat Song F, Altman DG, Glenny AM, Deeks JJ (2003) Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 326:472PubMedCrossRef Song F, Altman DG, Glenny AM, Deeks JJ (2003) Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 326:472PubMedCrossRef
17.
Zurück zum Zitat Song F, Harvey I, Lilford R (2008) Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions. J Clin Epidemiol 61:455–463PubMedCrossRef Song F, Harvey I, Lilford R (2008) Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions. J Clin Epidemiol 61:455–463PubMedCrossRef
18.
Zurück zum Zitat Kashiwagi A (2007) Reduction of microalbuminuria in patients with type 2 diabetes. The Shiga Microalbuminuria Reduction Trial (SMART). Diabetes Care 30:1581–1583PubMedCrossRef Kashiwagi A (2007) Reduction of microalbuminuria in patients with type 2 diabetes. The Shiga Microalbuminuria Reduction Trial (SMART). Diabetes Care 30:1581–1583PubMedCrossRef
19.
Zurück zum Zitat Estacio RO, Jeffers BW, Gifford N, Schrier RW (2000) Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 23(Suppl 2):B54–B64PubMed Estacio RO, Jeffers BW, Gifford N, Schrier RW (2000) Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 23(Suppl 2):B54–B64PubMed
20.
Zurück zum Zitat Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S (1996) Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 50:1641–1650PubMedCrossRef Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S (1996) Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 50:1641–1650PubMedCrossRef
21.
Zurück zum Zitat Chan JC, Ko GT, Leung DH et al (2000) Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int 57:590–600PubMedCrossRef Chan JC, Ko GT, Leung DH et al (2000) Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int 57:590–600PubMedCrossRef
22.
Zurück zum Zitat Lacourciere Y, Nadeau A, Poirier L, Tancrede G (1993) Captopril or conventional therapy in hypertensive type II diabetics. Three-year analysis. Hypertension 21:786–794PubMed Lacourciere Y, Nadeau A, Poirier L, Tancrede G (1993) Captopril or conventional therapy in hypertensive type II diabetics. Three-year analysis. Hypertension 21:786–794PubMed
23.
Zurück zum Zitat Shiba T, Inoue M, Tada H et al (2000) Delapril versus manidipine in hypertensive therapy to halt the type-2-diabetes-mellitus-associated nephropathy. Diabetes Res Clin Pract 47:97–104PubMedCrossRef Shiba T, Inoue M, Tada H et al (2000) Delapril versus manidipine in hypertensive therapy to halt the type-2-diabetes-mellitus-associated nephropathy. Diabetes Res Clin Pract 47:97–104PubMedCrossRef
24.
Zurück zum Zitat Heart Outcomes Prevention Evaluation (HOPE) Study Investigators (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253–259CrossRef Heart Outcomes Prevention Evaluation (HOPE) Study Investigators (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253–259CrossRef
25.
Zurück zum Zitat Baba S (2001) Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Res Clin Pract 54:191–201PubMedCrossRef Baba S (2001) Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Res Clin Pract 54:191–201PubMedCrossRef
26.
Zurück zum Zitat UK Prospective Diabetes Study Group (1998) Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 317:713–720CrossRef UK Prospective Diabetes Study Group (1998) Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 317:713–720CrossRef
27.
Zurück zum Zitat Fogari R, Mugellini A, Zoppi A et al (2005) Effect of successful hypertension control by manidipine or lisinopril on albuminuria and left ventricular mass in diabetic hypertensive patients with microalbuminuria. Eur J Clin Pharmacol 61:483–490PubMedCrossRef Fogari R, Mugellini A, Zoppi A et al (2005) Effect of successful hypertension control by manidipine or lisinopril on albuminuria and left ventricular mass in diabetic hypertensive patients with microalbuminuria. Eur J Clin Pharmacol 61:483–490PubMedCrossRef
28.
Zurück zum Zitat Fogari R, Preti P, Zoppi A et al (2002) Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. Am J Hypertens 15:1042–1049PubMedCrossRef Fogari R, Preti P, Zoppi A et al (2002) Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. Am J Hypertens 15:1042–1049PubMedCrossRef
29.
Zurück zum Zitat Marre M, Lievre M, Chatellier G, Mann JF, Passa P, Menard J (2004) Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ 328:495PubMedCrossRef Marre M, Lievre M, Chatellier G, Mann JF, Passa P, Menard J (2004) Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ 328:495PubMedCrossRef
30.
Zurück zum Zitat Nielsen FS, Rossing P, Gall MA, Skott P, Smidt UM, Parving HH (1997) Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 46:1182–1188PubMedCrossRef Nielsen FS, Rossing P, Gall MA, Skott P, Smidt UM, Parving HH (1997) Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 46:1182–1188PubMedCrossRef
31.
Zurück zum Zitat Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R (1998) Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 128:982–988PubMed Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R (1998) Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 128:982–988PubMed
32.
Zurück zum Zitat Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M (1993) Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 118:577–581PubMed Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M (1993) Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 118:577–581PubMed
33.
Zurück zum Zitat Lewis EJ, Hunsicker LG, Clarke WR et al (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851–860PubMedCrossRef Lewis EJ, Hunsicker LG, Clarke WR et al (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851–860PubMedCrossRef
34.
Zurück zum Zitat Brenner BM, Cooper ME, de Zeeuw D et al (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861–869PubMedCrossRef Brenner BM, Cooper ME, de Zeeuw D et al (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861–869PubMedCrossRef
35.
Zurück zum Zitat Bilous R, Chaturvedi N, Sjolie AK et al (2009) Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med 151(11–20):W13–W14 Bilous R, Chaturvedi N, Sjolie AK et al (2009) Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med 151(11–20):W13–W14
36.
Zurück zum Zitat Jerums G, Allen TJ, Campbell DJ et al (2004) Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with type 2 diabetes and microalbuminuria. Diabet Med 21:1192–1199PubMedCrossRef Jerums G, Allen TJ, Campbell DJ et al (2004) Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with type 2 diabetes and microalbuminuria. Diabet Med 21:1192–1199PubMedCrossRef
37.
Zurück zum Zitat Sjolie AK, Klein R, Porta M et al (2008) Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 372:1385–1393PubMedCrossRef Sjolie AK, Klein R, Porta M et al (2008) Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 372:1385–1393PubMedCrossRef
38.
Zurück zum Zitat Marre M, Puig JG, Kokot F et al (2004) Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. J Hypertens 22:1613–1622PubMedCrossRef Marre M, Puig JG, Kokot F et al (2004) Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. J Hypertens 22:1613–1622PubMedCrossRef
39.
Zurück zum Zitat Haller H, Ito S, Izzo JL Jr et al (2011) Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 364:907–917PubMedCrossRef Haller H, Ito S, Izzo JL Jr et al (2011) Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 364:907–917PubMedCrossRef
40.
Zurück zum Zitat Fogari R, Zoppi A, Corradi L et al (1999) Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function. J Hum Hypertens 13:47–53PubMedCrossRef Fogari R, Zoppi A, Corradi L et al (1999) Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function. J Hum Hypertens 13:47–53PubMedCrossRef
41.
Zurück zum Zitat Ahmad J, Siddiqui MA, Ahmad H (1997) Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 20:1576–1581PubMedCrossRef Ahmad J, Siddiqui MA, Ahmad H (1997) Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 20:1576–1581PubMedCrossRef
42.
Zurück zum Zitat Lebovitz HE, Wiegmann TB, Cnaan A, et al. (1994) Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int (Suppl 45):S150–S155 Lebovitz HE, Wiegmann TB, Cnaan A, et al. (1994) Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int (Suppl 45):S150–S155
43.
Zurück zum Zitat Ruggenenti P, Fassi A, Ilieva AP et al (2004) Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351:1941–1951PubMedCrossRef Ruggenenti P, Fassi A, Ilieva AP et al (2004) Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351:1941–1951PubMedCrossRef
44.
Zurück zum Zitat Mosconi L, Ruggenenti P, Perna A, Mecca G, Remuzzi G (1996) Nitrendipine and enalapril improve albuminuria and glomerular filtration rate in non-insulin dependent diabetes. Kidney Int Suppl 55:S91–S93PubMed Mosconi L, Ruggenenti P, Perna A, Mecca G, Remuzzi G (1996) Nitrendipine and enalapril improve albuminuria and glomerular filtration rate in non-insulin dependent diabetes. Kidney Int Suppl 55:S91–S93PubMed
45.
Zurück zum Zitat Ogawa S, Takeuchi K, Mori T, Nako K, Tsubono Y, Ito S (2007) Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy. Hypertens Res 30:325–334PubMedCrossRef Ogawa S, Takeuchi K, Mori T, Nako K, Tsubono Y, Ito S (2007) Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy. Hypertens Res 30:325–334PubMedCrossRef
Metadaten
Titel
Reno-protective effects of renin–angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis
verfasst von
P. Vejakama
A. Thakkinstian
D. Lertrattananon
A. Ingsathit
C. Ngarmukos
J. Attia
Publikationsdatum
01.03.2012
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 3/2012
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-011-2398-8

Weitere Artikel der Ausgabe 3/2012

Diabetologia 3/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.